Evotec Technologies Information

Evotec Technologies GmbH (ET) is a newly formed subsidiary of Evotec OAI AG focused on technology development and instrumentation. As an innovative technology provider the company serves current and future needs of all life sciences serving end-users and industrial partners. With a broad knowledge base - from drug discovery to diagnostics - ET offers innovative solutions for complex life sciences applications. Existing applications are improved and novel applications drive the development of novel technology. The company focuses on the seamless integration of hardware, software and bioware modules, combining cutting-edge technologies for measurement, miniaturisation and automation. To this end ET has available a unique set of validated core technologies which range from single molecule detection and cell processing to generic assays. ET's range of products include concepts, prototypes, modules and integrated systems, instruments, software, disposables and reagents. Technical and biological consulting and know-how transfer complete ET's portfolio. EVOscreen® Mark III, Evotec OAI's high-resolution uHTS system, represents only the most prominent example of elegant solutions resulting from this approach. It has been successfully integrated into Novartis', GlaxoSmithKline's and Pfizer's drug discovery units. Evotec Technologies employs 80 people, primarily in Hamburg, Germany. Subsidiaries are located in Düsseldorf and Berlin.